Roche’s tumour-agnostic therapy Rozlytrek approved in EU
Therapy has been approved to treat advanced NTRK fusion-positive solid tumours
Read More
Tag: NTRK gene fusion
EU nod for Bayer’s Vitrakvi
European regulators have cleared Bayer’s Vitrakvi (larotrectinib) as a treatment for solid tumours displaying an NTRK gene fusion.
Read More
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
